#ES­MO18: No­var­tis claims a key win in breast can­cer with PI3K drug alpelis­ib

MU­NICH — PI3K in­hibitors have had their prob­lems over the years, fail­ing some stud­ies, prov­ing to be dis­ap­point­ing in terms of dura­bil­i­ty in oth­ers. But No­var­tis $NVS be­lieves it may have come up with part of the an­swer with its lat­est da­ta on BYL719 (alpelis­ib) in com­bi­na­tion with ful­ves­trant.

Their al­pha-spe­cif­ic drug for PIK3CA mu­tat­ed HR+/HER2- ad­vanced breast can­cer, BYL719 plus ful­ves­trant near­ly dou­bled the pro­gres­sion-free sur­vival times for pa­tients, hit­ting 11 months com­pared to 5.7 months for a con­trol arm treat­ed on­ly with ful­ves­trant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER